Hormonal
GLP-1 receptor agonists promote weight loss, whereas DPP-4 inhibitors are generally weight-neutral, making GLP-1RAs more suitable for obese T2D patients.
If you have Type 2 Diabetes and struggle with weight, a GLP-1 injection is likely to help you lose weight while controlling blood sugar. You may experience nausea when starting, but this usually improves. DPP-4 inhibitor pills are an alternative if you cannot tolerate injections or side effects, but they will not help with weight loss.
Furthermore, as their actions are not restricted to stimulating insulin secretion, these agents have also been associated with additional non-glycaemic benefits such as weight loss, improvements in β-cell function and cardiovascular risk markers.
Why this rating
Supported by clinical trial data mentioned (e.g., incidence of nausea/vomiting, weight changes in trials).
Source
Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
Michael A. Nauck · Diabetes Obesity and Metabolism · 2015
DOI 10.1111/dom.12591
More from this paper
- GLP-1 receptor agonists and DPP-4 inhibitors both have a low risk of hypoglycemia when used as monotherapy due to their glucose-dependent mechanism of action.Strong
- GLP-1 receptor agonists (GLP-1RAs) provide superior glycemic control compared to DPP-4 inhibitors in type 2 diabetes, primarily due to higher pharmacological concentrations of GLP-1 and distinct tissue distribution patterns.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →